Newbury Pharmaceuticals AB (NEWBRY) — Cash Flow-to-Debt Ratio
Newbury Pharmaceuticals AB (NEWBRY) has a Cash Flow-to-Debt Ratio of 0.05x as of February 2026, meaning its operating cash flow of Skr2.26 Million could theoretically repay 0% of its total liabilities (Skr45.96 Million) in one year. See financial agility of Newbury Pharmaceuticals AB to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Newbury Pharmaceuticals AB Cash Flow-to-Debt Ratio (2021–2024)
Historical debt coverage capacity for Newbury Pharmaceuticals AB across 4 annual periods. For the full cash flow conversion analysis, see NEWBRY cash flow metrics.
Annual Cash Flow-to-Debt Ratio for Newbury Pharmaceuticals AB (2021–2024)
Year-by-year debt coverage analysis for Newbury Pharmaceuticals AB. Check earnings quality score of Newbury Pharmaceuticals AB to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.61x | Skr-23.71 Million | Skr38.95 Million | ▲ +38.3% |
| 2023 | -0.99x | Skr-23.23 Million | Skr23.54 Million | ▼ -19.3% |
| 2022 | -0.83x | Skr-15.00 Million | Skr18.14 Million | ▲ +11.7% |
| 2021 | -0.94x | Skr-4.07 Million | Skr4.34 Million | — |